Featured Stories
The 8th Annual Camp Sunshine Pediatric Low-grade Astrocytoma Brain Tumor Week 2019
The 8th Annual Camp Sunshine Pediatric Low-grade Astrocytoma Brain Tumor Week 2019 was a “SOLD OUT” family experience with PLGA families from 17…
Caught in the Act
First snapshots of cancer protein B-Raf illuminate basic biology, and can impact drug design for pediatric low grade glioma brain tumor…
Pediatric Brain Tumor Foundation and American Association for Cancer Research Announce RFP for Research Grant to Optimize Drug Dosing Strategies for PLGA Patients
The Pediatric Brain Tumor Foundation’s PLGA Fund and the American Association for Cancer Research (AARC) are excited to announce a request for…
Study Results: New PLGA Research Demonstrates the Power of Teamwork in Improving Outcomes for Kids with Brain Tumors
Children diagnosed with low-grade astrocytomas, the most common type of pediatric brain tumor, have close to 90 percent overall survival rates.…
Pediatric Brain Tumor Foundation and A Kids’ Brain Tumor Cure Join Forces to Change the Outcome for All Children with Brain Cancer
ASHEVILLE, N.C. and BOSTON -- The Pediatric Brain Tumor Foundation (PBTF) and A Kids’ Brain Tumor Cure (AKBTC, a/k/a PLGA Foundation) are merging…
Attainment of Functional and Social Independence in Adult Survivors of Pediatric CNS Tumors: A Report from the St Jude Lifetime Cohort Study
Beyond survival, achieving independence is a primary goal for adult survivors of pediatric CNS tumors. Researchers at St. Jude recently concluded a…
Research
- May 2018: Critical Mechanisms of Gene Regulation in Medulloblastoma
- March 2017: SickKids of Toronto, Dr. Uri Tabori: – Novel universal classification of childhood low grade gliomas using clinico-pathological and molecular methods.
- June 2016: DNA Analysis of Paediatric Low-Grade Astrocytomas Identifies Tumour-Specific Signature in Pilocytic Astrycotomas
- June 2016: Johns Hopkins Medical Center – Dr. Eric Raabe, Dr. Charles Eberhart, Dr. Fausto Rodriguez: Using Human Neural Stem Cells to Create Genetically Accurate Models of PLGG, Developing PLGG Models Using Patient-Derived Tumor Tissue, Dual mTOR/NOTCH inhibition as a Therapeutic Strategy for PLGG
- November 2015: Long Term Clinical Implications of PLGG Molecular Subgroups
- September 2015: Genomic Analysis of Matched Primary and Progressive Recurrent PLGAs
